The Quantellect read.As of Nov 19, 2026, 7 active firms cover Tenax Therapeutics Inc: 3 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $4.00 to $50.00 (about 12.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $17.17 sits 1092% above the current $1.44. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-1.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Neutral
Strong Buy00%
Buy343%
Neutral457%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.17
+1092.1% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.44 current
Highest Target$50.00
Average Target$17.17
Lowest Target$4.00
Detailed analyst forecasts for TENX
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 3 of 7 active firms rate TENX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TENX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.42 – $-0.33 · 3 analysts · +3% YoY
Next period, 3 analysts expect Tenax Therapeutics Inc to earn $-0.36 a share (range $-0.42 – $-0.33), versus $-0.35 a year earlier. Full-year consensus is $-1.39, growing to $-1.31 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tenax Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TENX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$50.00+3372.2% to target
Overall win rate
30%
+ Follow
#2
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$35.00+2330.6% to target
Overall win rate
35%
+ Follow
#3
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$5.00+247.2% to target
Overall win rate
28%
+ Follow
#4
Seamus Fernandez
Guggenheim
Neutral
No targeton TENX
Coverage
—
+ Follow
#5
OB
Olivia Brayer
Cantor Fitzgerald
Buy
$35.00+2330.6% to target
Coverage
—
+ Follow
TENX stock forecast FAQ
What is TENX's average 12-month price target?+
The 6 active firms with a live target average $17.17 for Tenax Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $4.00 low, as of Nov 19, 2026.
Is TENX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 7 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TENX?+
The Street-high target is $50.00 (Piper Sandler), and the Street-low is $4.00 (Canaccord Genuity). The average of all 6 active-firm targets is $17.17.
How many active Wall Street firms cover TENX?+
7 active firms have a recognized rating on Tenax Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TENX?+
Among analysts who currently cover TENX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #339). Their current call is Buy with a $50.00 target.
What is Tenax Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.42 – $-0.33) across 3 analysts. Full-year EPS is projected at $-1.39, rising to $-1.31 the following year.
How much revenue is Tenax Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TENX lately?+
As of Nov 19, 2026, 3 of 7 active firms rate TENX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TENX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.